876589-82-1

Upstream product

• 1493-27-2 ortho-nitrofluorobenzene 
• 177906-48-8 trans-N-Boc-1,4-cyclohexanediamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2615-25-0 trans-1,4-cyclohexyldiamine 
• 88-73-3 2-Chloronitrobenzene 

Downstream Products

• 1456507-11-1 1-((1r,4r)-4-((2-hydroxy-2-phenylpropyl)amino)cyclohexyl)-1H-benzo[d]imidazol-2(3H)-one 
• 1456505-02-4 (R+S) 5-methyl-3-((1r,4r)-4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)cyclohexyl)-5-phenyloxazolidin-2-one 
• 1456506-59-4 tert-butyl ((1r,4r)-4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)cyclohexyl)carbamate 
• 1456506-58-3 1-((1r,4r)-4-aminocyclohexyl)-1H-benzo[d]imidazol-2(3H)-one hydrochloride 
• 876589-83-2 tert-butyl ((1r,4r)-4-((2-aminophenyl)amino)cyclohexyl)carbamate 

Relevant academic research and scientific papers

OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF

Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein.

CHEMICAL COMPOUNDS

The present invention provides novel compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind specifically to the chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 and/or CCR5 of a target cell.